A Phase 3b Multicenter, Open-label Abiraterone Acetate Long-term Safety Study
Latest Information Update: 25 Jul 2022
At a glance
- Drugs Abiraterone acetate (Primary) ; Prednisone
- Indications Prostate cancer
- Focus Adverse reactions
- Sponsors Janssen Research & Development
- 27 May 2021 Status changed from active, no longer recruiting to completed.
- 03 May 2018 Planned End Date changed from 9 Apr 2018 to 9 Apr 2021.
- 03 May 2018 Planned primary completion date changed from 9 Apr 2018 to 9 Apr 2021.